38
Participants
Start Date
July 14, 2021
Primary Completion Date
July 31, 2025
Study Completion Date
July 31, 2025
Abatacept
Abatacept is a selective costimulation modulator, inhibiting T lymphocyte activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Orencia solution supplied in a prefilled syringe should be refrigerated at 2C to 8C (36F to 46F). Orencia should not be used beyond the expiration date on the prefilled syringe. The product should be protected from light by storing in the original package until time of use. The prefilled syringe should not be frozen.
Placebo
The composition of the placebo for Orencia is the same as the active study drug without the abatacept. The placebo will be packaged and labeled as described above for the Orencia prefilled syringes. To maintain the blind, injection volumes will be the same as the active treatment.
RECRUITING
Duke University Health System, Durham
RECRUITING
University of South Florida, Tampa
RECRUITING
Cincinnati Children's Hospital Medical Center, Cincinnati
RECRUITING
Mayo Clinic, Rochester
RECRUITING
University of California, San Francisco, San Francisco
RECRUITING
Lahey Hospital and Medical Center, Burlington
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Children's Hospital Medical Center, Cincinnati
OTHER